A HALF-HOUR scan could help bladder cancer patients be treated almost twice as fast, a groundbreaking study has found. Using an MRI check to help tackle tumours — instead of invasive surgery — cut

MRI scan could fast-track patients for bladder cancer treatment, study finds - An MRI instead of a surgical procedure helped speed up the wait between diagnosis and treatment, UK research has found

Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder cancer. Using the immunotherapy drug durvalumab before and after surgery reduced the recurrence of operable bladder cancer by a third,

Researchers have introduced an innovative surgical technique for treating bladder cancer that could revolutionize the field of urological oncology.

Bladder cancer presents through various symptoms, ranging from subtle changes to more noticeable signs. While some symptoms might seem minor, understanding

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a lid on their growth?

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click for our IBRX stock update.

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name Imfinzi) is a treatment for non small cell lung cancer (NSCLC) but is also being trialled in other cancers.

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research suggests that initial MRI imaging and biopsy could be used to reduce the time patients wait.

A “game-changer” study claims bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive. Patients with advanced (muscle-invasive) bladder cancer had significantly less risk of cancer progressing or returning when treated with durvalumab,

The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC) who have not received the vaccine for the cancer.

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the disease returning by a third...